Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm

Sumanta Kumar Pal, Stephen Williams, David Y. Josephson, Courtney Carmichael, Nicholas J. Vogelzang, David I. Quinn

Research output: Contribution to journalReview article

36 Citations (Scopus)

Abstract

With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress in treating this disease. However, the goal of cure remains elusive, and the agents nearest approval (i.e., axitinib and tivozanib) abide by the same paradigm as existing drugs (i.e., inhibition of VEGF or mTOR signaling). The current review will focus on investigational agents that diverge from this paradigm. Specifically, novel immunotherapeutic strategies will be discussed, including vaccine therapy, cytotoxic T-lymphocyte antigen 4 (CTLA4) blockade, and programmed death-1 (PD-1) inhibition, as well as novel approaches to angiogenesis inhibition, such as abrogation of Ang/Tie-2 signaling. Pharmacologic strategies to block other potentially relevant signaling pathways, such as fibroblast growth factor receptor or MET inhibition, are also in various stages of development. Although VEGF and mTOR inhibition have dramatically improved outcomes for patients with mRCCs, a surge above the current plateau with these agents will likely require exploring new avenues.

Original languageEnglish (US)
Pages (from-to)526-537
Number of pages12
JournalMolecular Cancer Therapeutics
Volume11
Issue number3
DOIs
StatePublished - Mar 2012
Externally publishedYes

Fingerprint

Renal Cell Carcinoma
Vascular Endothelial Growth Factor A
CTLA-4 Antigen
Active Immunotherapy
Fibroblast Growth Factor Receptors
Therapeutics
Pharmaceutical Preparations
tivozanib
axitinib

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Novel therapies for metastatic renal cell carcinoma : Efforts to expand beyond the VEGF/mTOR signaling paradigm. / Pal, Sumanta Kumar; Williams, Stephen; Josephson, David Y.; Carmichael, Courtney; Vogelzang, Nicholas J.; Quinn, David I.

In: Molecular Cancer Therapeutics, Vol. 11, No. 3, 03.2012, p. 526-537.

Research output: Contribution to journalReview article

Pal, Sumanta Kumar ; Williams, Stephen ; Josephson, David Y. ; Carmichael, Courtney ; Vogelzang, Nicholas J. ; Quinn, David I. / Novel therapies for metastatic renal cell carcinoma : Efforts to expand beyond the VEGF/mTOR signaling paradigm. In: Molecular Cancer Therapeutics. 2012 ; Vol. 11, No. 3. pp. 526-537.
@article{66a6ba40f5654a8881b219e46903a665,
title = "Novel therapies for metastatic renal cell carcinoma: Efforts to expand beyond the VEGF/mTOR signaling paradigm",
abstract = "With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress in treating this disease. However, the goal of cure remains elusive, and the agents nearest approval (i.e., axitinib and tivozanib) abide by the same paradigm as existing drugs (i.e., inhibition of VEGF or mTOR signaling). The current review will focus on investigational agents that diverge from this paradigm. Specifically, novel immunotherapeutic strategies will be discussed, including vaccine therapy, cytotoxic T-lymphocyte antigen 4 (CTLA4) blockade, and programmed death-1 (PD-1) inhibition, as well as novel approaches to angiogenesis inhibition, such as abrogation of Ang/Tie-2 signaling. Pharmacologic strategies to block other potentially relevant signaling pathways, such as fibroblast growth factor receptor or MET inhibition, are also in various stages of development. Although VEGF and mTOR inhibition have dramatically improved outcomes for patients with mRCCs, a surge above the current plateau with these agents will likely require exploring new avenues.",
author = "Pal, {Sumanta Kumar} and Stephen Williams and Josephson, {David Y.} and Courtney Carmichael and Vogelzang, {Nicholas J.} and Quinn, {David I.}",
year = "2012",
month = "3",
doi = "10.1158/1535-7163.MCT-11-0806",
language = "English (US)",
volume = "11",
pages = "526--537",
journal = "Molecular Cancer Therapeutics",
issn = "1535-7163",
publisher = "American Association for Cancer Research Inc.",
number = "3",

}

TY - JOUR

T1 - Novel therapies for metastatic renal cell carcinoma

T2 - Efforts to expand beyond the VEGF/mTOR signaling paradigm

AU - Pal, Sumanta Kumar

AU - Williams, Stephen

AU - Josephson, David Y.

AU - Carmichael, Courtney

AU - Vogelzang, Nicholas J.

AU - Quinn, David I.

PY - 2012/3

Y1 - 2012/3

N2 - With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress in treating this disease. However, the goal of cure remains elusive, and the agents nearest approval (i.e., axitinib and tivozanib) abide by the same paradigm as existing drugs (i.e., inhibition of VEGF or mTOR signaling). The current review will focus on investigational agents that diverge from this paradigm. Specifically, novel immunotherapeutic strategies will be discussed, including vaccine therapy, cytotoxic T-lymphocyte antigen 4 (CTLA4) blockade, and programmed death-1 (PD-1) inhibition, as well as novel approaches to angiogenesis inhibition, such as abrogation of Ang/Tie-2 signaling. Pharmacologic strategies to block other potentially relevant signaling pathways, such as fibroblast growth factor receptor or MET inhibition, are also in various stages of development. Although VEGF and mTOR inhibition have dramatically improved outcomes for patients with mRCCs, a surge above the current plateau with these agents will likely require exploring new avenues.

AB - With six agents approved for metastatic renal cell carcinoma (mRCC) within the past 5 years, there has undoubtedly been progress in treating this disease. However, the goal of cure remains elusive, and the agents nearest approval (i.e., axitinib and tivozanib) abide by the same paradigm as existing drugs (i.e., inhibition of VEGF or mTOR signaling). The current review will focus on investigational agents that diverge from this paradigm. Specifically, novel immunotherapeutic strategies will be discussed, including vaccine therapy, cytotoxic T-lymphocyte antigen 4 (CTLA4) blockade, and programmed death-1 (PD-1) inhibition, as well as novel approaches to angiogenesis inhibition, such as abrogation of Ang/Tie-2 signaling. Pharmacologic strategies to block other potentially relevant signaling pathways, such as fibroblast growth factor receptor or MET inhibition, are also in various stages of development. Although VEGF and mTOR inhibition have dramatically improved outcomes for patients with mRCCs, a surge above the current plateau with these agents will likely require exploring new avenues.

UR - http://www.scopus.com/inward/record.url?scp=84859416603&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84859416603&partnerID=8YFLogxK

U2 - 10.1158/1535-7163.MCT-11-0806

DO - 10.1158/1535-7163.MCT-11-0806

M3 - Review article

C2 - 22351744

AN - SCOPUS:84859416603

VL - 11

SP - 526

EP - 537

JO - Molecular Cancer Therapeutics

JF - Molecular Cancer Therapeutics

SN - 1535-7163

IS - 3

ER -